389 related articles for article (PubMed ID: 36613919)
1. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.
Leal AF; Benincore-Flórez E; Rintz E; Herreño-Pachón AM; Celik B; Ago Y; Alméciga-Díaz CJ; Tomatsu S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613919
[TBL] [Abstract][Full Text] [Related]
2. Current and new therapies for mucopolysaccharidoses.
Penon-Portmann M; Blair DR; Harmatz P
Pediatr Neonatol; 2023 Feb; 64 Suppl 1():S10-S17. PubMed ID: 36464587
[TBL] [Abstract][Full Text] [Related]
3. From bedside to cell biology: a century of history on lysosomal dysfunction.
Coutinho MF; Matos L; Alves S
Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening and diagnosis of mucopolysaccharidoses.
Tomatsu S; Fujii T; Fukushi M; Oguma T; Shimada T; Maeda M; Kida K; Shibata Y; Futatsumori H; Montaño AM; Mason RW; Yamaguchi S; Suzuki Y; Orii T
Mol Genet Metab; 2013; 110(1-2):42-53. PubMed ID: 23860310
[TBL] [Abstract][Full Text] [Related]
5. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for Mucopolysaccharidoses.
Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
[TBL] [Abstract][Full Text] [Related]
8. Craniovertebral junction pathological features and their management in the mucopolysaccharidoses.
Sganzerla EP; Giussani C; Grimaldi M; Parini R; Ingelmo P; Trezza A; Visocchi M
Adv Tech Stand Neurosurg; 2014; 40():313-31. PubMed ID: 24265052
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of Mucopolysaccharidoses, an Update.
Fecarotta S; Tarallo A; Damiano C; Minopoli N; Parenti G
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260444
[TBL] [Abstract][Full Text] [Related]
10. Current and potential therapeutic strategies for mucopolysaccharidoses.
Noh H; Lee JI
J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression-Related Changes in Morphologies of Organelles and Cellular Component Organization in Mucopolysaccharidoses.
Gaffke L; Pierzynowska K; Rintz E; Cyske Z; Giecewicz I; Węgrzyn G
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803318
[TBL] [Abstract][Full Text] [Related]
12. Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.
Nan H; Park C; Maeng S
Biomed Res Int; 2020; 2020():2408402. PubMed ID: 33344633
[No Abstract] [Full Text] [Related]
13. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses.
Kakkis E; Marsden D
Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020
[TBL] [Abstract][Full Text] [Related]
14. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
[TBL] [Abstract][Full Text] [Related]
15. Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses.
Fachel FNS; Frâncio L; Poletto É; Schuh RS; Teixeira HF; Giugliani R; Baldo G; Matte U
Adv Drug Deliv Rev; 2022 Dec; 191():114616. PubMed ID: 36356930
[TBL] [Abstract][Full Text] [Related]
16. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
Thomas R; Kermode AR
Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
[TBL] [Abstract][Full Text] [Related]
17. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
Shapiro EG; Jones SA; Escolar ML
Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
[TBL] [Abstract][Full Text] [Related]
18. Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.
Kubaski F; Suzuki Y; Orii K; Giugliani R; Church HJ; Mason RW; Dũng VC; Ngoc CT; Yamaguchi S; Kobayashi H; Girisha KM; Fukao T; Orii T; Tomatsu S
Mol Genet Metab; 2017 Mar; 120(3):247-254. PubMed ID: 28065440
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses.
Losada Díaz JC; Cepeda Del Castillo J; Rodriguez-López EA; Alméciga-Díaz CJ
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905715
[TBL] [Abstract][Full Text] [Related]
20. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
